Neoandrographolide

Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity^{[1][2][3][4][5]}. In Vitro:Neoandrographolide (0-30 μM, 6 days) inhibits osteoclast differentiation-related gene expression of NFATc1, c-Fos, CTSK and MMP9, inhibits RANKL-induced osteoclasts maturation in murine bone marrow macrophage^[2].
Neoandrographolide (10-90 μM, 24 h) inhibits the expression of inflammatory factors TNF-α and IL-1β^[3].
Neoandrographolide (7.5-150 μM, 24-36 h) inhibits PMA (HY-18739)-stimulated respiratory burst, inhibits LPS (HY-D1056)-induced TNF-α and NO production in cell RAW264.7^[4]. In Vivo:Neoandrographolide (15-30 mg/kg, ip, 3 times a week for 8 weeks) alleviates OVX-induced osteoporosis in mouse models^[2].
Neoandrographolide (10 mg/kg, ip, once a day for 6 days) alleviates the ischemia-reperfusion injury in mouse models^[3].
Neoandrographolide (50-150 mg/kg, po, single dose) inhibits Dimethyl benzene-induced ear edema, exhibits anti-inflammatory activity in mouse models^[4].